CYAD - Celyad's CAR T therapy shows 10 months OS in early-stage colorectal cancer trial

Celyad Oncology (CYAD) rises 8% in premarket on the heels of updated data from Phase 1 alloSHRINK trial evaluating CYAD-101, its allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR T candidate, administered concurrently with FOLFOX chemotherapy for the treatment of refractory metastatic colorectal cancer. Data were presented at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium.Median overall survival ((OS)) and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively.Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the highest dose level of 1x109 cells per infusion.Emergence of new T cell clones in the peripheral blood T cell repertoire four months after therapy was observed in patients analyzed from the highest dose level who experienced either a confirmed partial response or stable disease.Recommended dose of 1x109 CYAD-101 cells per infusion will be

For further details see:

Celyad's CAR T therapy shows 10 months OS in early-stage colorectal cancer trial